Similar results were observed in the Selpercatinib study, a shorter median PFS was observed in concurrent TP53 mutated patients.40 The negative action of TP53 concurrent mutation to TKI monotherapy in NSCLC has been reported, and TKI plus chemotherapy may offer greater benefits to these patients.41,42 Therefore, the strategy of combination therapy may be an alternative option for TP53 co-mutation patients. This evidence concerns the gene TP53 and non-small cell lung carcinoma.